COPD中特应性与哮喘的临床表型:SPIROMICS与COPDGene的荟萃分析
特应性患病率分别为35%和36%,与哮喘重叠不足50%。荟萃分析显示,非特应性哮喘患者症状评分最差、急性加重风险最高,而单纯特应性和特应性哮喘患者不良结局风险未增加。
要点
- COPD患者中特应性与哮喘重叠不足50%。
- 非特应性哮喘患者症状评分最差且急性加重风险最高。
- 单纯特应性和特应性哮喘患者不良结局风险未增加。
核心结论
- COPD患者中特应性与哮喘重叠不完全,非特应性哮喘与不良结局和急性加重风险相关,而单纯特应性和特应性哮喘风险较低。
研究设计与样本
- 比较组按特应性和哮喘状态定义:两者均无、单纯特应性、特应性哮喘、非特应性哮喘;特应性定义为对10种过敏原或混合物中任一种特异性IgE阳性(≥0.35 KU/L),哮喘定义为自我报告医生诊断的当前哮喘。
- 采用多变量回归分析(线性、逻辑回归和零膨胀负二项回归),调整年龄、性别、种族、肺功能、吸烟状态、包年吸烟量和吸入性糖皮质激素使用,分别在各队列分析后使用荟萃分析合并调整结果。
主要发现
- SPIROMICS和COPDGene中COPD患者的特应性患病率分别为35%和36%,特应性与哮喘重叠不足50%。
- 荟萃分析中,与非特应性非哮喘组相比,非特应性哮喘组症状评分最差:圣乔治呼吸问卷总分效应量4.2(95%CI 0.4-7.9),COPD评估测试评分效应量2.8(95%CI 0.089-5.4)。
- 非特应性哮喘组急性加重风险最高:发生率比1.41(95%CI 1.05-1.88)。
- 单纯特应性和特应性哮喘组未显示不良结局风险增加。
临床怎么用
- 在COPD患者中应区分特应性与哮喘状态,非特应性哮喘表型需关注症状控制和急性加重预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the concordance of atopy with asthma COPD overlap. Among individuals with COPD, a better understanding of the phenotypes characterized by asthma overlap and atopy is needed to better target therapies. RESEARCH QUESTION: What is the overlap between atopy and asthma status among individuals with COPD, and how are categories defined by the presence of atopy and asthma status associated with clinical and radiologic phenotypes and outcomes in the Genetic Epidemiology of COPD Study (COPDGene) and Subpopulation and Intermediate Outcome Measures in COPD Study (SPIROMICS)? STUDY DESIGN AND METHODS: Four hundred three individuals with COPD from SPIROMICS and 696 individuals from COPDGene with data about specific IgEs to 10 common allergens and mixes (simultaneous assessment of combination of allergens in similar category) were included. Comparison groups were defined by atopic and asthma status (neither, atopy alone, atopic asthma, nonatopic asthma, with atopy defined as any positive specific IgE (≥0.35 KU/L) to any of the 10 allergens or mixes and asthma defined as self-report of doctor-diagnosed current asthma). Multivariable regression analyses (linear, logistic, and zero inflated negative binomial where appropriate) adjusted for age, sex, race, lung function, smoking status, pack-years smoked, and use of inhaled corticosteroids were used to determine characteristics of groups and relationship with outcomes (exacerbations, clinical outcomes, CT metrics) separately in COPDGene and SPIROMICS, and then adjusted results were combined using meta-analysis. RESULTS: The prevalence of atopy was 35% and 36% in COPD subjects from SPIROMICS and COPDGene, respectively, and less than 50% overlap was seen between atopic status with asthma in both cohorts. In meta-analysis, individuals with nonatopic asthma had the most impaired symptom scores (effect size for St. George's Respiratory Questionnaire total score, 4.2; 95% CI, 0.4-7.9; effect size for COPD Assessment Test score, 2.8; 95% CI, 0.089-5.4), highest risk for exacerbations (incidence rate ratio, 1.41; 95% CI, 1.05-1.88) compared with the group without atopy or asthma. Those with atopy and atopic asthma were not at increased risk for adverse outcomes. INTERPRETATION: Asthma and atopy had incomplete overlap among former and current smokers with COPD in COPDGene and SPIROMICS. Nonatopic asthma was associated with adverse outcomes and exacerbation risk in COPD, whereas groups having atopy alone and atopic asthma had less risk.
引用
- Putcha N, Fawzy A, Matsui EC, et al. Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene. Chest. 2020. PMID: 32450244. doi:10.1016/j.chest.2020.04.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。